Ipsen’s Sohonos Clinches First US Approval For Ultra-Rare Bone Disorder
Despite Chequered Past
Just a month after an EU rejection, the French drugmaker’s oral retinoic acid receptor gamma agonist Sohonos has won a US thumbs up for the treatment of fibrodysplasia ossificans progressiva, an ultra-rare disorder that turns soft tissue into bone.
